Abstracts Archive - Page 2605 of 2607 - ACR Meeting Abstracts

Abstract Number: 2672 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Analysis Reveals Genetic Heterogeneity of Sjögren’s Syndrome (SS) According to Specific Subphenotypes and Ancestry
Lindsey A. Criswell¹, Kimberly E. Taylor², Caitlin McHugh³, Cathy Laurie³, Kimberly Doheny⁴, Mi Y. Lam², Joanne Nititham⁵, Laura Bierut⁶, Emily L. Harris⁷, Alan N. Baer⁸, Stephen Challacombe⁹, Yi Dong¹⁰, Hector Lanfranchi¹¹, Morten Schiodt¹², M. Srinivasan¹³, Susumu Sugai¹⁴, Hisanori Umehara¹⁵, Frederick B. Vivino¹⁶, Zhao Yan¹⁷, Stephen Shiboski², Troy Daniels¹⁸, John S. Greenspan¹⁹, Caroline Shiboski¹⁹ and SICCA²⁰, ¹Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³University of Washington, Biostatistics, Seattle, WA, ⁴Center for Inherited Disease Research, Baltimore, MD, ⁵Medicine, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁶Psychiatry, Washington University, St. Louis, MO, ⁷National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Kings College London, London, United Kingdom, ¹⁰Dept of Rheumatology, Peking Univ Med Coll Hospital, East City Beijing, China, ¹¹University of Buenos Aires, Buenos Aires, Argentina, ¹²Righospitalet, Copenhagen, Denmark, ¹³Aravind Eye Hospital, Madurai, India, ¹⁴Kanazawa Medical University, Ishikawa, Japan, ¹⁵Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Kanazawa, Japan, ¹⁶Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ¹⁷Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁸Orofacial Sciences, Box 0422, UCSF Schools of Medicine & Dentistry, San Francisco, CA, ¹⁹Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ²⁰San Francisco, CA
Background/Purpose: Our goal is to define the contribution of genetic factors to SS and related subphenotypes. Methods: We studied 2,459 participants in the Sjögren’s International…
Abstract Number: 2673 • 2012 ACR/ARHP Annual Meeting
Sibling Relative Risk and Heritability of Sjögren’s Syndrome: A Nationwide Population Study in Taiwan
Chang-Fu Kuo¹, Matthew J. Grainge², Kuang-Hui Yu³, Lai-Chu See⁴, Shue-Fen Luo³, Ana M. Valdes⁵, I-Jun Chou⁶, Hsiao-Chun Chang³, Weiya Zhang¹ and Michael Doherty⁷, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁴Department of Public Health, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Although familial aggregation has been found in many autoimmune diseases, the evidence for familial aggregation in Sjögren’s syndrome is lacking. The aims of this…
Abstract Number: 2674 • 2012 ACR/ARHP Annual Meeting
Cis-Expression Quantitative Trait Loci Analysis of Dysregulated Interferon-Pathway Genes Identifies HLA-C and OAS1 As Novel Candidates for Susceptibility to Sjögren’s Syndrome
He Li¹, John A. Ice², Jennifer A. Kelly³, Indra Adrianto², Stuart B. Glenn⁴, Kimberly S. Hefner⁵, Evan G. Vista⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, Glen D. Houston⁹, David M. Lewis¹⁰, Michael Rohrer⁸, Pamela Hughes⁸, John B. Harley¹¹, Courtney G. Montgomery², James Chodosh⁷, James A. Lessard¹², Juan-Manuel Anaya¹³, Barbara M. Segal¹⁴, Nelson L. Rhodus¹⁵, Lida Radfar¹⁶, Mark B. Frank¹⁷, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁷Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Valley Bone and Joint Clinic, Grand Forks, ND, ¹³School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of Europeans. Dysregulation of interferon…
Abstract Number: 2675 • 2012 ACR/ARHP Annual Meeting
Oral and Gut Microbiota Influence Immune Responses to Sjogren’s Syndrome Associated Antigen Ro60
Agnieszka Szymula¹, Barbara Szczerba¹, Harini Bagavant¹, Shu-Man Fu² and Umesh Deshmukh³, ¹Department of Medicine, University of Virginia, Charlottesville, VA, ²University of Virginia, Charlottesville, VA, ³Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: Autoantibodies reactive against Ro60 protein are often found in patients with Sjogren’s syndrome. This study was undertaken to investigate the role of oral and…
Abstract Number: 2676 • 2012 ACR/ARHP Annual Meeting
Long-Term Humoral Autoimmunity to Ro60 in Primary Sjögren’s Syndrome Is Driven by Clonal Succession
Rhianna Lindop¹, Isabell Bastian¹, Georgia Arentz¹, Lauren Thurgood¹, Andrew Whyte¹, Tim, K. Chataway², Michael Jackson¹ and Tom Gordon¹, ¹Immunology, Flinders Medical Centre and Flinders University, Adelaide, Australia, ²Human Physiology, School of Medicine, Flinders University, Adelaide, Australia
Background/Purpose : Long-lived humoral autoimmunity to Ro60 is considered a hallmark of primary Sjögren’s syndrome (SS), but the mechanism by which this immunity is sustained over…
Abstract Number: 2677 • 2012 ACR/ARHP Annual Meeting
IL-23 Controls Autoimmunity by Facilitating Clearance of Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD2 Mice
Hao Li¹, Hui-Chen Hsu², Qi Wu³, PingAr Yang³, Jun Li⁴, Daniel Cua⁵, Mohamed Oukka⁶ and John D. Mountz⁷, ¹Microbiology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁶Pediatrics, Seattle, WA, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Failure to clear apoptotic bodies is a central pathogenic mechanism for SLE. We have observed that spontaneous systemic autoimmunity and lupus in BXD2 mice…
Abstract Number: 2678 • 2012 ACR/ARHP Annual Meeting
Novel Nuclear Export Inhibitors Deplete Autoreactive Plasma Cells and Protect Mice with Lupus-Like Disease From Nephritis
Teresa Owen¹, Wensheng Wang¹, Dilara McCauley², Laura Strojny¹, Jennifer Hossler¹, Javier Rangel-Moreno³, Michael Kauffman², Sharon Shacham⁴ and Jennifer H. Anolik⁵, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Karyopharm, Therapeutics Inc., Natick, MA, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴Karyopharm Therapeutics Inc., Natick, MA, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Most therapies currently used to treat systemic lupus erythematosus (SLE) and B cell targeted therapies under development do not effectively target plasma cells and…
Abstract Number: 2679 • 2012 ACR/ARHP Annual Meeting
Loss of Caspase 8 in Dendritic Cells Induces a Systemic Lupus Erythematosus-Like Disease That Is Independent of the Necroptosome
Carla M. Cuda¹, Alexander V. Misharin², Rana Saber², G. Kenneth Haines III³, Jack Hutcheson⁴, Chandra Mohan⁵ and Harris R. Perlman⁶, ¹Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine/Rheumatology, Northwestern University, Chicago, IL, ³Department of Pathology, Yale University, New Haven, CT, ⁴Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁶Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-organ, destructive autoimmune disease characterized by pathogenic autoantibodies. Though it is accepted that dendritic cells (DCs) play an…
Abstract Number: 2680 • 2012 ACR/ARHP Annual Meeting
Soluble Receptor for Advanced Glycation End Products Alleviates Nephritis in NZB/WF1 Mice
Sang-Won Lee¹, Kyu-Hyoung Park¹, Sungha Park², Ji-Hye Kim¹, Sung-You Hong², Soo Kon Lee³, Donghoon Choi² and Yong-Beom Park⁴, ¹Internal Medicine, Yonse University College of Medicine, Seoul, South Korea, ²Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ³Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁴Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: The receptor for advanced glycation end products (RAGE) is a pattern-recognition receptor that interacts with multiple ligands such as high mobility group box 1…
Abstract Number: 2681 • 2012 ACR/ARHP Annual Meeting
Blocking the Serum Protease Inhibitor Activity of Plasminogen Activator Inhibitor-1 Protects Mice From Development of Glomerulonephritis in a Model of Lupus Nephritis
Brian Naiman¹, Tracy Delaney¹, Lily Cheng², Philip Brohawn², Chris Morehouse², Christopher Groves¹, Isabelle de-Mendez³, Dominic Corkill⁴, Anthony Coyle⁵, Ronald Herbst¹ and Jane Connor¹, ¹Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³Research, MedImmune, LLC, Cambridge, United Kingdom, ⁴Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Cambridge, United Kingdom, ⁵Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA
Background/Purpose: Lupus nephritis is an autoimmune disorder which is characterized by extracellular matrix accumulation driven by immune complex deposition and in which thrombosis and sclerosis…
Abstract Number: 2682 • 2012 ACR/ARHP Annual Meeting
Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Systemic Lupus Erythematosus
Tomohiro Koga¹, Kunihiro Ichinose², Masayuki Mizui³, José C. Crispín⁴ and George C. Tsokos⁴, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with SLE exhibit abnormal signaling upon TCR engagement and have an altered gene expression profile. Accordingly, the regulation of several transcription factors…
Abstract Number: 2683 • 2012 ACR/ARHP Annual Meeting
Interferon-Associated Cytokine and Chemokine Expression in Patients with Serologically Active Clinically Quiescent (SACQ) Systemic Lupus Erythematosus (SLE)
Amanda J. Steiman¹, Murray B. Urowitz², Dominique Ibanez², Carolina Landolt-Marticorena³, Dafna D. Gladman⁴ and Joan E. Wither⁵, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ⁵1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Interferon-α (IFN-α) plays a prominent pro-inflammatory role in SLE. Studies suggest clinical/serologic discordance may illuminate SLE pathophysiology: peripheral IFN-α production is blunted in autoantibody-producing,…
Abstract Number: 2684 • 2012 ACR/ARHP Annual Meeting
Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR2 Antibodies As Surrogate Markers for CNS Disease Severity in SLE
Shunsei Hirohata, Yoshiyuki Arinuma and Eisuke Ogawa, Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Neuropsychiatric manifestations occur in approximately one-half of patients with SLE and may cause substantial impairment of quality of life as well as disability. Among…
Abstract Number: 2685 • 2012 ACR/ARHP Annual Meeting
Overall and Cause Specific Mortality in Patients with Systemic Lupus Erythematosus. A Meta-Analysis of Observational Studies
Marko Yurkovich¹, Kateryna Vostretsova² and J. Antonio Avina-Zubieta³, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE), is a chronic autoimmune condition. It has the potential to affect any organ system and can be associated with severe…
Abstract Number: 2646 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia
John B. Wong¹ and Chenchen Wang², ¹Medicine/Clinical Decision Making, Tufts Medical Center, Boston, MA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Although fibromyalgia is associated with substantial annual direct medical and indirect productivity costs, the cost-effectiveness of treatments for fibromyalgia remains understudied. A randomized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].